Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 17 of 22 for:    "Thalassemia" | "Deferiprone"

Pharmacokinetic Study of Deferiprone in Paediatric Patients (DEEP-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01740713
Recruitment Status : Completed
First Posted : December 4, 2012
Results First Posted : January 11, 2017
Last Update Posted : January 11, 2017
Sponsor:
Collaborator:
European Commission
Information provided by (Responsible Party):
Consorzio per Valutazioni Biologiche e Farmacologiche

Brief Summary:
Deferiprone (DFP) is the most extensively studied oral iron chelator to date. It has been authorised in Europe in 1999 for the treatment of iron overload in patients with beta-thalassaemia major when DFO is contraindicated or inadequate. Despite a wide experience of DFP there are limited experimental data available on DFP in children and no pharmacokinetic data in children under 6 years of age. On the basis of the existing data in adults and adolescent, in the DEEP-1 trial a pharmacokinetic bridging model was developed to support the dose selection in children aged less than 6 years affected by transfusion dependent haemoglobinopathies. The study consisted of two phases, namely an experimental phase, during which patients received a single dose and a modeling phase, during which PK data obtained after single dose in patients < 6 years of age were analysed in conjunction with historical PK data in adults and older children and adolescents. The model-based analysis of the data obtained after single dose enabled the assessment of the dosing regimen required for the purpose of accurate pharmacokinetic bridging. The ratio between the predicted systemic exposure parameters (AUC and Cmax) in the target population and reference group were used as basis for recommendation of the dose in the target population.

Condition or disease Intervention/treatment Phase
Chronic Iron Overload Drug: Deferiprone, dose level 1 Drug: Deferiprone, dose level 2 Drug: Deferiprone, dose level 3 Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Official Title: Multi-centre, Oral Single Dose Experimental and Modelling Study to Evaluate the Pharmacokinetics of Deferiprone in Patients Aged From 1 Month to Less Than 6 Years of Age Affected by Transfusion-dependent Haemoglobinopathies.
Study Start Date : December 2012
Actual Primary Completion Date : December 2013
Actual Study Completion Date : February 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Iron
Drug Information available for: Deferiprone

Arm Intervention/treatment
Experimental: Deferiprone, dose level 1
single dose level of 8.3 mg/kg every 8 hours for a corresponding total daily dose of 25 mg/kg/day.
Drug: Deferiprone, dose level 1
a solution at 80 mg/mL will be administered orally
Other Name: DFP

Experimental: Deferiprone, dose level 2
single dose level of 16.7 mg/kg every 8 hours for a corresponding total daily dose of 50 mg/kg/day.
Drug: Deferiprone, dose level 2
a solution at 80 mg/mL will be administered orally
Other Name: DFP

Experimental: Deferiprone, dose level 3
single dose level of 33.3 mg/kg every 8 hours for a corresponding total daily dose of 100 mg/kg/day.
Drug: Deferiprone, dose level 3
a solution at 80 mg/mL will be administered orally
Other Name: DFP




Primary Outcome Measures :
  1. CL/F [ Time Frame: Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration) ]
    Plasma clearance after oral administration. The parameter was estimated through a population pharmacokinetic model, during which concentration data obtained after single oral dose ( at 3 dose levels) of DFP in patients aged from 1 month to less than 6 years of age.

  2. AUC (0-8h) [ Time Frame: Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration) ]
    Area under concentration versus time curve from 0 to 8 h post dosing. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.

  3. V/F [ Time Frame: Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration) ]
    volume of distribution after oral administration. The parameter was estimated through a population pharmacokinetic model, during which concentration data obtained after single oral dose ( at 3 dose levels) of DFP in patients aged from 1 month to less than 6 years of age

  4. Tmax [ Time Frame: Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration) ]
    Time at which the maximum concentration (Cmax) is reached. Secondary pharmacokinetic parameters such as Cmax, Min, Tmax, Css and AUC (0-8h) were derived based on the individual predicted concentration vs. time profiles.

  5. Ka [ Time Frame: Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration) ]
    Absorption rate constant. The parameter was estimated through a population pharmacokinetic model, during which concentration data obtained after single oral dose ( at 3 dose levels) of DFP in patients aged from 1 month to less than 6 years of age.

  6. Cmax [ Time Frame: Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration) ]
    Maximum concentration reached in plasma. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.

  7. Css [ Time Frame: Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration) ]
    Plasma concentration reached at steady state. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.

  8. Cmin [ Time Frame: Day 1 of single dose treatment (6 sampling time range: from predose up to 8h post first administration) ]
    Minimum plasma concentration. Secondary pharmacokinetic parameter derived on the basis of the individual predicted concentration vs. time profiles, through the pop-PK model.


Secondary Outcome Measures :
  1. Adverse Events [ Time Frame: from drug administration up to 8 days post treatment ]
    All the medical occurrences that started after the administration of the drug



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients in a chronic transfusional program who have received at least 150 ml/kg/year of packed red blood cells (corresponding approximately to 12 transfusions) and on current treatment with DFO, DFX, DFP; aged from 1 month to less than 6 years; or
  • Patients naïve to any chelation treatment who have received not less than 150 ml/kg of packed red blood cells (corresponding to approximately 12 transfusions) and have ferritin levels > 800 ng/mL, aged from 1 month to less than 6 years; or
  • Patients who meet the transfusion criteria (150 ml/kg/year corresponding approximately to 12 transfusions) and have known intolerance or contraindication to DFO

And if all of the following criteria apply:

  • Patients affected by any hereditary haemoglobinopathies requiring chronic transfusion therapy including but not limited to thalassaemia and sickle cell disease
  • Written informed consent obtained from their legal guardian on the patient's behalf in accordance with the national legislations. According to his/her capability, patient's informed assent will be collected

Exclusion Criteria:

  • Patient with known intolerance or contraindication to the trial treatment
  • Patient with Hb levels less than 8g/dl (entry may be delayed until values return to normal)
  • Patient with platelet count <100.000/mm3 or absolute neutrophil count <1.500/mm3 (entry may be delayed until values return to normal)
  • Patient with evidence of abnormal liver function (ALT level >5 times the upper normal limit during six months preceding enrolment; entry may be delayed until values return to normal)
  • iron overload from causes other than transfusional haemosiderosis
  • severe heart dysfunction secondary to iron overload defined as the occurrence of heart failure or severe arrhythmia or as indicated by cardiac T2* lower than 10 ms, if recent MRI data is available,
  • Patient with serum creatinine level above the upper normal limit at screening; entry may be delayed until values return to normal.
  • Serological evidence of chronic hepatitis B (presence of HBe Ag, HBsAg, HBcAb-IgM, in the absence of HBsAb).
  • History of significant medical or psychiatric disorder that may impair compliance with the requirements of the protocol.
  • The patient has received another investigational drug within 30 days prior to this study.
  • Patient with a pre-existing condition or any other surgical or medical condition which might significantly interfere with normal gastrointestinal and hepatic function that could alter the absorption, metabolism, and/or excretion of the study drug.
  • Patient with a known history of HIV seropositivity.
  • Fever and other signs/symptoms of infection in the 10 days before drug administration(treatment day)
  • Concomitant use of other iron chelators or trivalent cation-dependent medicinal products such as aluminium-based antacids.
  • Patient with a chronic condition that does not allow suspension of related treatment from starting of washout until drug is administered.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01740713


Locations
Layout table for location information
Cyprus
Department of Medical and Public Health Services of the Ministry of Health
Nicosia, Cyprus
Egypt
Cairo Univesity Paediatric Hospital
Cairo, Egypt
Italy
Azienda Ospedaliero-Universitaria Consorziale
Bari, Italy, 70124
Azienda Ospedaliera Antonio Cardarelli
Napoli, Italy, 80131
Azienda Ospedaliera Di Padova
Padova, Italy, 35127
Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello
Palermo, Italy, 90146
Clinica Pediatrica Universita' - Asl 1
Sassari, Italy, 07100
Sponsors and Collaborators
Consorzio per Valutazioni Biologiche e Farmacologiche
European Commission
Investigators
Layout table for investigator information
Study Chair: Oscar Della Pasqua Universiteit Leiden, The Netherlands
Principal Investigator: Giovanni Carlo Del Vecchio Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Italy

Layout table for additonal information
Responsible Party: Consorzio per Valutazioni Biologiche e Farmacologiche
ClinicalTrials.gov Identifier: NCT01740713     History of Changes
Other Study ID Numbers: DEEP-1
First Posted: December 4, 2012    Key Record Dates
Results First Posted: January 11, 2017
Last Update Posted: January 11, 2017
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Consorzio per Valutazioni Biologiche e Farmacologiche:
chronic iron overload
hereditary haemoglobinopathy
beta thalassaemia major
Additional relevant MeSH terms:
Layout table for MeSH terms
Deferiprone
Hemoglobinopathies
Iron Overload
Iron Metabolism Disorders
Metabolic Diseases
Hematologic Diseases
Genetic Diseases, Inborn
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action